TSC1 and lung carcinoma: Another gene hit, Tsc1, was further investigated by Huang et al., who found that TSC1/2 deficiency upregulated PD-L1 expression, making TSC1/2-deficient lung cancer cells more responsive to anti-PD-1 therapy (Huang et al., 2022).